Furthermore, nearly all cases of PEL exhibit TP53 immunohistochemical positivity, which serves as the basis for its designation within the broad category of AML with mutated TP53 by the International Consensus Classification. This evidence concerns the gene TP53 and primary effusion lymphoma.